STOCK TITAN

NANOBIOTIX to Present at the 5th Annual Evercore ISI HealthCONx Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

NANOBIOTIX, a late-stage clinical biotechnology company, announced that its co-founder Laurent Levy and CFO Bart Van Rhijn will participate in a virtual fireside chat at the 5th annual Evercore ISI HealthCONx Conference on December 1, 2022, at 9:15 AM ET / 3:15 PM CET. The chat will be available live on the company's website and archived for 90 days. NANOBIOTIX focuses on enhancing cancer treatment outcomes through its innovative nanoparticle platform, especially targeting head and neck cancers.

Positive
  • None.
Negative
  • None.

PARIS and CAMBRIDGE, Mass., Nov. 15, 2022 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that Laurent Levy, co-founder and chairman of the executive board, and Bart Van Rhijn, chief financial officer, will participate in a virtual fireside chat at the 5th annual Evercore ISI HealthCONx Conference on Thursday, December 1, 2022, at 9:15 AM ET / 3:15 PM CET.

The fireside chat will be webcast live from the events page of the Investors section of the Company’s website. A replay of the webcast will be archived and available for 90 days following the event.

About NANOBIOTIX
Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The company is leveraging its proprietary nanoparticle platform, including its lead product candidate, radiotherapy activated NBTXR3, to develop a pipeline of therapeutic options designed to enhance local and systemic control of solid tumors with an initial focus on the treatment of head and neck cancers.

For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter.

Contacts

Nanobiotix

Communications Department
Brandon Owens
VP, Communications
+1 (617) 852-4835
contact@nanobiotix.com


Investor Relations Department
Kate McNeil
SVP, Investor Relations
+1 (609) 678-7388
investors@nanobiotix.com

Media Relations

FR – Ulysse Communication
Pierre-Louis Germain
+ 33 (0) 6 64 79 97 51
plgermain@ulysse-communication.com

Global – LifeSci Advisors
Ligia Vela-Reid
+44 (0) 7413825310
Lvela-reid@lifesciadvisors.com

 


FAQ

What is the date and time of the NANOBIOTIX fireside chat at the Evercore ISI HealthCONx Conference?

The NANOBIOTIX fireside chat is scheduled for December 1, 2022, at 9:15 AM ET / 3:15 PM CET.

Who from NANOBIOTIX will participate in the fireside chat?

Laurent Levy, co-founder and chairman, and Bart Van Rhijn, CFO, will participate in the fireside chat.

Where can I watch the NANOBIOTIX fireside chat?

The fireside chat will be webcast live on the Investors section of the NANOBIOTIX website.

How long will the NANOBIOTIX fireside chat be available for replay?

A replay of the NANOBIOTIX fireside chat will be available for 90 days following the event.

What is the focus of NANOBIOTIX's cancer treatment research?

NANOBIOTIX focuses on using its proprietary nanoparticle platform to enhance treatment for solid tumors, particularly head and neck cancers.

Nanobiotix S.A. American Depositary Shares

NASDAQ:NBTX

NBTX Rankings

NBTX Latest News

NBTX Stock Data

158.09M
46.87M
13.54%
0.06%
Biotechnology
Healthcare
Link
United States of America
Paris